<DOC>
	<DOCNO>NCT01272557</DOCNO>
	<brief_summary>This study prospective , randomize , open-label , multicenter phase IIB trial order determine time progression combination therapy sorafenib plus doxorubicin standard-of-care sorafenib advance HCC amenable non-systemic treatment .</brief_summary>
	<brief_title>Sorafenib Plus Doxorubicin Versus Sorafenib Alone Treatment Advanced Hepatocellular Carcinoma : Randomized Phase II Trial</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Nonresectable locally advanced metastasize HCC Subjects must least one tumor lesion meet follow criterion : lesion accurately measure least one dimension accord RECIST 1.1 lesion previously treat local therapy ( surgery , radiation therapy , hepatic arterial therapy , chemoembolization , radiofrequency ablation , percutaneous ethanol injection cryoablation ) Subjects received local therapy ( surgery , radiation therapy , hepatic arterial therapy , chemoembolization , radiofrequency ablation , percutaneous ethanol injection cryoablation ) eligible , provide target lesion subject local therapy . Local therapy must complete least 4 week prior baseline scan . Confirmation disease histology Liver function : Child Pugh stage A/B ( 57 point ) Tumor stage : BCLC stage C ( well ) ECOG performance status 02 Life expectancy least 12 week Age ≥ 18 year Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen within 4 week start treatment : Hemoglobin ≥ 9.0 g/dl Absolute neutrophil count ( ANC ) ≥1.500/mm3 Platelet count ≥ 70.000/μl Total bilirubin ≤ 3 mg/dl ALT AST ≤ 5 x upper limit normal Alkaline phosphatase &lt; 4 x upper limit normal PTINR/PTT &lt; 1.5 x upper limit normal [ Patients therapeutically anticoagulated agent warfarin , phenprocoumon heparin NOT allow participate ] Serum creatinine ≤ 1.5 x upper limit normal Signed date informed consent start study specific procedure Patients eligible resection transplantation Previous concurrent cancer distinct primary site histology cancer evaluate study . However cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis T1 ) cancer curatively treat &gt; 3 year prior entry permit Serious myocardial dysfunction : define absolute leave ventricular ejection fraction ( LVEF ) &lt; 50 % , instable coronaropathy ( MI 6 mo prior study entry allow ) , cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) Inadequately control hepatic complication ( varix , encephalopathy ) Untreated active Hepatitis B include HBsAg carrier ; patient start ( prophylactic ) antiviral medication even without current viral replication Concomitant therapy interferon ( e.g . Hepatitis B/C ) study phase Uncontrolled arterial hypertension systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 90 mm Hg despite optimal treatment Known history HIV infection Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) Symptomatic metastatic brain meningeal tumor ( unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect tumor time study entry ) Patients seizure disorder require medication ( steroids antiepileptic ) History organ allograft Patients evidence history bleed diathesis Thrombotic embolic event within last 6 month Serious nonhealing wound , fracture , ulcer Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Women enrol trial must use adequate barrier birth control measure course trial least 6 month last administration doxorubicin 2 month last administration sorafenib . Severe concomitant disease psychiatric disorder Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result Known severe hypersensitivity sorafenib , doxorubicin excipients Patients unable swallow oral medication Incompliance / contraindication study medication Excluded therapy medication , previous concomitant : Previous systemic therapy HCC Anticancer chemotherapy immunotherapy target therapy ( except study medication ) study within 4 week study entry . Radiotherapy study within 3 week start study drug . ( Palliative radiotherapy allow ) . Major surgery within 4 week start study Autologous bone marrow transplant stem cell rescue within 4 month study Use biologic response modifier , GCSF , within 3 week study entry . [ GCSF hematopoietic growth factor may use management acute toxicity febrile neutropenia clinically indicate discretion investigator , however may substitute require dose reduction . ] [ Patients take chronic erythropoietin permit provide dose adjustment undertaken within 2 month prior study study ] Patients receive anticoagulation therapy ASS &gt; 100 mg/d Investigational drug therapy outside trial within 4 week study entry Prior exposure study drug . Any St. John 's wort containing remedy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>HCC</keyword>
</DOC>